Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 8/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimethylammonium SCHEMBL11673563 | 0.97 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA | |
| Trimethylammonium SCHEMBL1263576 | 0.97 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA | |
| Trimethylammonium SCHEMBL1274146 | 0.97 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA | |
| Trimethylammonium SCHEMBL16738271 | 0.97 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA | |
| Trimethylammonium SCHEMBL320626 | 0.97 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA | |
| Trimethylammonium SCHEMBL25438207 | 0.97 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA | |
| Trimethylammonium SCHEMBL876163 | 0.97 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA | |
| Trimethylammonium SCHEMBL28043 | 0.97 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA | |
| Trimethylammonium SCHEMBL2181606 | 0.97 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA | |
| Trimethylammonium SCHEMBL1150051 | 0.97 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2012500187-A | — | — | 2012-01-05 | — | — | JP | claimed |
| US-20110172455-A1 | PROCESS FOR PREPARING CINACALCET AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | IND-SWIFT LABORATORIES LIMITED (IN) | 2011-07-14 | — | — | US | claimed |
| EP-2310352-A2 | PROCESS FOR PREPARING CINACALCET AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | Ind-Swift Laboratories Limited (IN) | 2011-04-20 | — | — | EP | claimed |
| WO-2010004588-A2 | PROCESS FOR PREPARING CINACALCET AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | IND-SWIFT LABORATORIES LIMITED (IN) | 2010-01-14 | — | — | WO | claimed |
| CN-105492623-A | Method for measuring cholesterol in high-density lipoprotein, and reagent for use in said method | SEKISUI MEDICAL CO LTD | 2016-04-13 | — | — | CN | disclosed |
| US-20110172455-A1 | PROCESS FOR PREPARING CINACALCET AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | IND-SWIFT LABORATORIES LIMITED (IN) | 2011-07-14 | — | — | US | disclosed |
| EP-2310352-A2 | PROCESS FOR PREPARING CINACALCET AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | Ind-Swift Laboratories Limited (IN) | 2011-04-20 | — | — | EP | disclosed |
| WO-2010004588-A2 | PROCESS FOR PREPARING CINACALCET AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | IND-SWIFT LABORATORIES LIMITED (IN) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172455-A1 | PROCESS FOR PREPARING CINACALCET AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | CA9, SI, REN | TSHR 4112/4885THRB 4833/4885DNM1 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.